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Abstract
Background: Generic drugs are used by millions of patients for economic reasons, so their evaluation must be highly
transparent.
Objective: To assess the quality of reporting of bioequivalence trials comparing generic to brand-name drugs.
Methodology/Principal Findings: PubMed was searched for reports of bioequivalence trials comparing generic to brand-
name drugs between January 2005 and December 2008. Articles were included if the aim of the study was to assess the
bioequivalency of generic and brand-name drugs. We excluded case studies, pharmaco-economic evaluations, and validation
dosage assays of drugs. We evaluated whether important information about funding, methodology, location of trials, and
participants werereported. Wealsoassessed whetherthecriteriarequiredbytheFoodandDrug Administration (FDA)andthe
European Medicine Agency (EMA) to conclude bioequivalence were reported and that the conclusions were in agreement
with the results. We identified 134 potentially relevant articles but eliminated 55 because the brand-name or generic drug
status of the reference drug was unknown. Thus, we evaluated 79 articles. The funding source and location of the trial were
reported in 41% and 56% of articles, respectively. The type of statistical analysis was reported in 94% of articles, but the
methods to generate the randomization sequence and to conceal allocation were reported in only 15% and 5%, respectively.
In total, 65 articles of single-dose trials (89%) concluded bioequivalence. Of these, 20 (31%) did not report the 3 criteria within
the limits required by the FDA and 11 (17%) did not report the 2 criteria within the limits required by the EMA.
Conclusions/Significance: Important information to judge the validity and relevance of results are frequently missing in
published reports of trials assessing generic drugs. The quality of reporting of such trials is in need of improvement.
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Introduction
To lower healthcare costs, substituting brand-name drugs for low-
cost bioequivalent generic drugs has greatly increased. In the United
States, generic drugs represented 47% of all prescriptions dispensed in
1999, 61% in 2006 and 69% by the end of 2008 [1]. According to the
Generic Pharmaceutical Association, the use of generics saved the US
healthcare system approximately $121 billion in 2008. Generic and
brand-name drugs have the same active principle, but generic drugs
could differ in inert binder, color of tablet and manufacturing process.
To approve new generic drugs, the US Food and Drug Administration
( F D A )a n dt h eE u r o p e a nM e d i c i n eA g e n c y( E M A )r e l i e so nt h er e s u l t s
of bioequivalence trials based on pharmacokinetic criteria: rate of
absorption as determined by the peak plasma concentration (Cmax),
area under the plasma concentration–time curve from time 0 to time
t=endofthestudy(AUC| 0t ot ) and to infinity (AUC|0 to infinity). The
FDA requires the 90% confidence intervals (CIs) of the ratio of the
generic and brand name drugs for these 3 criteria to be within 80%
and 125% [2] whereas the EMA [3] requires only Cmax and AUC|0
to t. Reports of some studies and letters have warned about generic-
drug substitution, suggesting lower efficacy and higher rates of adverse
events [4,5,6,7,8,9], but data are scarce, and most studies had a low
level of evidence. More importantly, drug companies may be
implicated in this anti-generic-drug campaign [10]. Recently, 2
meta-analyses [11,12] comparing the efficacy of brand-name and
generic drugs in the field of cardiovascular diseases and seizures did not
show any superiority of the brand-name over the generic drugs.
In this study, we aimed to investigate published reports of
bioequivalence trials comparing generic to brand-name drugs to
assess their quality of reporting.
Methods
Search strategy
We performed an electronic search of MEDLINE via PubMed
to identify all reports of trials published from Jan. 1, 2005, to Dec.
31, 2008. The following search equation was used: "Therapeutic
Equivalency"[Mesh] OR "Drugs, Generic"[Mesh] OR "Biological
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proprietary OR brand name OR innovator AND (Humans[Mesh]
AND English[lang] AND ("2005/01/01"[PDat]: "2008/12/
31"[PDat])). We also electronically searched the table of contents
of journals (Arzneimittel-forschung, International Journal of
Clinical Pharmacology and Therapeutics, Clinical Therapeutics)
known to publish reports of bioequivalence trials assessing generic
drugs for additional references missed during the PubMed search.
Selection of relevant articles
One of us (A.V.D.M) selected potentially relevant articles after
screening the titles and abstracts. In case of uncertain eligibility,
the full text was screened. Articles were included if the aim of the
study was to assess the bioequivalency of generic and brand-name
drugs. We excluded case studies, pharmaco-economic evaluations,
meta-analyses, commentaries and validation dosage assays of
drugs. Studies were also excluded if the active principle was not
approved by the FDA or EMA and if they involved animals or in
vitro analysis.
If information about the products being tested lacked, FDA or
EMA websites were searched to obtain further information.
A second reviewer (A.D) assessed all articles of uncertain
eligibility, and the final decision for inclusion was obtained by
consensus between the 2 reviewers.
Data extraction
We generated a standardized data collection form based on the
guidelines of the FDA [2] and EMA [3], a review of the literature
and a priori discussion. Before data extraction, as a calibration
exercise, 2 members of the team (A.D., A.V.D.M) evaluated a
random set of 10 reports. All disagreements were resolved by
consensus, and the form was modified accordingly.
The following data were extracted from each article:
1. General characteristics of the selected studies: category of the
journal (pharmacology, general medicine, specialty medicine)
and year of publication; whether the funding source was
reported and whether it was public or private.
2. Characteristics of the drugs: the class of drug according to the
Anatomical Therapeutic Chemical classification [13]; the
name of the reference drug and whether the drug had a
narrow therapeutic index (NTI) (i.e., a drug with less than a
50% difference between the minimum toxic concentration,
minimum effective concentration in blood and median effective
dose[14]) and whether this information was reported in the
article. For NTI drugs, the EMA requires narrower limits than
for non-NTI drugs: the 90% CIs for the generic to brand-name
ratio should be between 90% and 111% instead of between
80% and 125%.[3].
3. Study design: whether the study design was reported, the type
of design (i.e., randomized controlled, parallel or cross-over),
and the sample size. We also noted whether a registration
number in an international database was reported.
4. Administration of the drugs: whether the mode of administra-
tion of the drugs was reported: the route of administration (i.e.,
oral, parenteral), the dose of the drugs (i.e., single or multiple)
and how the drugs were administered (i.e., under fasting or fed
condition).
5. Methodology of the study: whether the methods used to
generate the randomization sequence and conceal allocation
were reported and adequate according to the definitions
provided by the Cochrane Collaboration [15]; whether study
participants, care providers and outcome assessors were
reported to be blinded to the treatment arm; whether the
number of participants excluded from data analysis and the
reasons for exclusion were reported; whether a sample size
calculation was reported; and whether the statistical analysis
performed was reported and the type of analysis (i.e., ANOVA,
t test).
6. Setting and population characteristics: whether the article
reported the country where the study was performed and the
main characteristics of the study participants (age, weight,
height, sex, exclusion criteria).
7. Results and conclusions: the results of the trial (i.e., 90% CI of
the generic to brand-name ratio for Cmax, AUC|0t otand,
AUC|0 to infinity of the generic to brand-name drug and the
conclusions (i.e., bioequivalence, non-bioequivalence, unclear).
The same reviewer (A.V.D.M) independently completed all the
data extractions. A second member of the team (A.D.) reviewed a
random sample of 30 articles to assess inter-rater reliability.
PRISMA checklist is provided in Appendix S4.
Statistical analysis
The analysis was descriptive. Data were summarized as number
and percentages for qualitative variables, and median, interquar-
tile range (IQR) and range for continuous variables. Inter-rater
agreement between the 2 assessors (A.V.D.M. and A.D.) was
assessed by the kappa coefficient for qualitative variables. All
analyses involved use of R v2.9.0.
Results
Selection of relevant trials
A flow chart of the selected articles of trials comparing generic
to brand-name drugs is in Figure 1. Briefly, the electronic search
yielded 5,522 citations, 215 articles were selected for further
evaluation, and a final 79 reports of bioequivalence trials were
selected after reading the full text. Of these, 63 articles described
non-NTI drugs (Appendix S1) and 16 NTI drugs (Appendix S2).
Only 5 articles reported that the drug was an NTI drug. In total,
55 articles (Appendix S3) out of 134 (41%) were eliminated
because only the compendium name of the reference drug was
reported, and we could not determine whether the reference drug
was a brand-name or another generic drug. In general, the kappa
for data extraction was good, ranging from 0.71 to 1.
General characteristics of the trials
Table S1 provides the general characteristics of the selected
bioequivalence trials. Most of the studies were published in
pharmacology journals (78%). The studies concerned a wide range
of pharmacological areas, the most common being study of anti-
infective agents for systemic use (37%) and of the cardiovascular
system (18%) and nervous system (14%).
Funding was reported in 41% of the articles and was private in
25%. In total, 73 reports (92%) described single-dose administra-
tion and 6 (8%) multiple-dose administration. In 66 (83%), the
administration was under the fasting condition.
Study design and methodology
Table S2 shows the study design and methodology of the
bioequivalence trials. Only one trial reported a registration
number in an international database. The study design was
reported in most articles (99%) and was a randomized cross-over
controlled trial in these studies. The median sample size was 24
(IQR 24 to 28; range 12 to 70). A sample size calculation was
reported in 27 articles (34%). In one article, the authors reported
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study because they could not conclude bioequivalence with the
initial sample size.
The method used to generate the randomization sequence was
reported and adequate in 12 articles (15%). Allocation conceal-
ment was reported and adequate in 4 articles (5%). Blinding of
study participants, care providers and outcome assessors was
reported in 13 (16%), 11 (14%) and 6 (8%) articles, respectively. In
total, 38 articles (48%) reported that data for all participants were
included in the analysis and 18 (23%) that some participants were
excluded from analysis; the remaining 23 (29%) gave no
information on potential exclusion. The statistical analysis test
was reported in 73 articles (94%) and was ANOVA for 67 articles
(86%) and t test for 6 (8%). Six articles (6%) did not report which
test was used. For the 67 articles reporting ANOVA, 78%
described taking into account period, 73% sequence, 66%
formulation and 66% subject within sequence.
Setting and population characteristics
As shown in Table S3, the location of the study was reported in
44 articles (56%). Of these, 22 (50%) studies were performed in
Asia. In total, 73 articles (92%) described the inclusion of
exclusively healthy participants. Six articles about NTI drugs
(38%) described the inclusion of non-healthy participants. The age
of participants was reported in 62 articles (78%), and the median
age was 28 years (IQR 23 to 33). Exclusion criteria were reported
Figure 1. Flow diagram of the selection of reports of trials comparing generic to brand-name drugs published between 2005 and
2008.
doi:10.1371/journal.pone.0023611.g001
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(57%), significant psychiatric or medical disease (56%) and
positivity for hepatitis B or C virus (50%) and HIV (40%).
Results and conclusions for single-dose bioequivalence
trials (Table S4)
Among the reports of single-dose trials (n=73), for 65 (89%) the
conclusion was bioequivalence, for 7 (10%) non-bioequivalence,
and for one, the conclusion was unclear. For the articles with
bioequivalence conclusion, 45 (69%) reported 90% CIs within the
limits required for the 3 criteria as required by the FDA, 15 (23%)
reported appropriate 90% CIs for 2 criteria, 8 of which reported
both Cmax and AUC|0t otas required by the EMA, and 2 (2%) did
not report any 90% CIs for the criteria. Two articles (3%) with
bioequivalence conclusions described 90% CIs outside the limits. In
one trial, the 90% CI for Cmax for the ratio was between 77% and
133%, which is authorized by EMA for highly variable drugs (i.e.,
drugs exhibiting intra-subject variability greater than 30%).
Figures 2, 3 and 4 show the details of the 90% CIs for the ratio of
generic to brand-name for Cmax, AUC|0t otand, AUC|0 to infinity of
generic to brand-name drugs for all reports of single-dose trials with
bioequivalence conclusions separately for NTI and non-NTI drugs.
Discussion
Generic drugs are used by many patients for economic reasons,
so their evaluation must be highly transparent. We systematically
reviewed the quality of reporting of bioequivalence trials
comparing generic to brand-name drugs and found it to be
overall poor. In 41% of articles, the name of the reference drug
was not given. Information was insufficient for funding source,
important items for assessing the risk of bias within trials and
country where the trial was performed. More importantly, a
substantial number of articles of single-dose trials concluding
bioequivalence did not report the 90% CI for the criteria required
by the Health authorities.
The objectives and methodology of bioequivalence trials differ
greatly from those of noninferiority and equivalence trials.
Bioequivalence trials are usually randomized crossover trials
including a small sample of healthy volunteers aiming to
demonstrate that 2 molecules are chemically bioequivalent on
Figure 2. Ratio and 90% confidence intervals for the Cmax of single-dose bioequivalence trials with a conclusion of bioequivalence.
Black squares indicate ratio; horizontal lines, 90% CI. The size of each square reflects the number of participants enrolled. Limits of acceptance
required by both FDA and EMA for confidence intervals of the ratio are within 80% and 125% of the ratio of the generic to brand-name drug.
doi:10.1371/journal.pone.0023611.g002
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determined by the peak plasma concentration (Cmax), area under
the plasma concentration–time curve from time 0 to time t=end
of the study (AUC|0 to t) and to infinity (AUC|0 to infinity).
Limits used to conclude bioequivalence are fixed by regulatory
agencies. Noninferiority and equivalence trials aim to demonstrate
that the experimental treatment is not clinically different from the
comparator (an active control treatment) by more than a pre-
specified small amount known as the equivalence margin and
which is fixed by the investigators of the trial and varies greatly
among trials. Equivalence trials are usually parallel-group trials
including a large number of patients (the smaller the margin, the
larger the number of patients) and clinical outcomes. Some
previous methodological reviews [16,17] assessed the quality of
reporting for noninferiority and/or equivalence trials and showed
important deficiencies, but to our knowledge, this is the first review
focusing on bioequivalence trials.
Substituting brand-name for generic for drugs is crucial for
reducing healthcare costs. As an example, in the United States, the
use of generic drugs has saved the healthcare system more than
$734 billion between 1999 and 2008, with approximately $121
billion in savings in 2008 alone. So, the development of generic
drugs is important. Because this development leads to the use of
generics by millions of patients, the evaluation of these drugs must
be highly transparent, with registration of trials, publication of
results of registered trials and adequate reporting of results. Our
aim was not to discuss the methodology of trials assessing generic
drugs but to determine whether the variables currently recom-
mended to conclude bioequivalence were adequately reported.
Only one article reported a trial’s registration number in an
international database. Given the number of existing generic
drugs, it is likely that bioequivalence data are not published for
most of them. During the study period, 1,661 new generic drugs
were approved by the FDA [18]. Reports of trials assessing generic
drugs were not available on FDA or EMA websites. Moreover, our
sample of published reports of bioequivalence trials included
mostly positive bioequivalence trial results. So publication bias
[19] may also affect bioequivalence trials comparing generic to
brand-name drugs because it is not likely that only 10% of trials
failed to demonstrate bioequivalence.
Figure 3. Ratio and 90% confidence intervals for the AUC|0t otof single-dose bioequivalence trials with a conclusion of
bioequivalence. Black squares indicate ratio; horizontal lines, 90% CI. The size of each square reflects the number of participants enrolled. Limits of
acceptance required by both the US Food and Drug Administration (FDA) and the European Medicine Agency (EMA) for confidence intervals of the
ratio are within 80% and 125% of the ratio for the generic to brand-name drug.
doi:10.1371/journal.pone.0023611.g003
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name of the reference drug, so we could not ascertain whether the
reference drug was the brand-name or another generic drug. The
readers need to know which comparator was used because
equivalence trials require the efficacy of the reference treatment to
be well established [20,21]. If the reference drug is not the brand-
name drug, bio-creep [20] leading to a significant loss of activity
compared to the brand-name drug could occur, as was shown in 2
simulation studies [22,23]. The consequences can be important for
patients, especially for drugs with an NTI, because small changes
in systemic concentration can lead to substantial changes in
clinical response and toxicity of the drug.
Our results also show lack of transparency in published reports
of trials. Important information such as funding source, country
where the trial was performed and details about the methodology
were frequently missing. Knowing which population was used and
how the trial was performed (i.e., randomization method, whether
data for some participants were excluded from analysis) is essential
to critically judge whether the results are valid and reproducible.
More importantly, about one-third of articles of single-dose trials
concluding bioequivalence did not report adequately 90% CIs for
the 3 criteria required by the FDA. As the EMA required only two
of these criteria, also about 20% of these articles did not report
these criteria. If the required information to conclude bioequiv-
alence is missing, readers cannot judge whether the conclusion is
reliable.
Our study has some limitations. The search period was short,
2005 to 2008. Nevertheless, our study relied on guidelines
published relatively recently by the FDA, in 2003, and by the
EMA, in 2001 and updated in 2008. We used PubMed only to
identify relevant trials, so our search may not have been exhaustive
because of incomplete journal coverage. Embase covers pharma-
cology journals well and has indexing terms suited to this topic, so
future reviews should also involve searching this database.
However, the search strategy we used to obtain articles revealed
only 1 additional article in Embase that could have been included
in our study. Our sample included few articles of bioequivalence
trials performed in Europe or North America. We do not have any
satisfactory explanation for this situation.
In conclusion, because generic drugs are necessary and are used
by many people, we argue for increased transparency of published
results of trials comparing generic to brand-name drugs. Efforts
Figure 4. Ratio and 90% confidence intervals for the AUC|0 to infinity of single-dose bioequivalence trials with a conclusion of
bioequivalence. Black squares indicate ratio; horizontal lines, 90% CI. The size of each square reflects the number of participants enrolled. Limits of
acceptance required by FDA for confidence intervals of the ratio are within 80% and 125% of the ratio of the generic to brand-name drug.
doi:10.1371/journal.pone.0023611.g004
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registration of trial protocols and publication of trial results. The
reference drug used should be systematically documented as the
drug with demonstrated efficacy. Important information for
judging both internal and external validity should be systematically
reported, as should the 90% CIs for the 3 criteria (mean Cmax ,
AUC|0t ot , and AUC|0 to infinity) for the ratio of generic to brand-
name drug required by the FDA, so that readers can judge the
reliability of the conclusions.
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